Abstract
Since the mid-1990s, pharma companies have devised their sales and marketing
strategies based on Rx data. However, with the introduction of the AMA's
Prescribing Data Restriction Program (PDRP) opt-out program in July 2006,
pharma companies need to evaluate the impact of PDRP violation, mediate their
PDRP compliance strategies, and revisit their existing Sales Force
Effectiveness (SFE) practices. With the introduction of the PDRP, the use of
physician Rx data by pharmaceutical companies will never be the same again.
The PDRP prohibits access to physician-level Rx data, which directly impacts
First Line Managers, Sales Representatives, and anyone else that accesses or
distributes physician Rx data.
Arrowhead Publishers' report The Prescribing Data Restriction Program:
Critical Assessment and Best Practices estimates the impact of PDRP
violations, analyzes the use of Rx data, gauges awareness in the marketplace
and benchmarks the best practices towards PDRP compliance.
Key features of this report:
- Best practices towards PDRP compliance
- Outline of the practical implications of the PDRP
- Industry perceptions of the PDRP (survey research)
Reasons to purchase this report:
- Understand what other pharma companies are doing to comply with the PDRP.
- Learn the financial rewards associated with successful PDRP compliance
strategies
- Gain a better understanding of the program and its implications for the
pharma industry
- Understand the areas of impact of PDRP violations, and inefficient PDRP
compliance strategies
| 
View Cart
